The state of Wisconsin currently has 3 active clinical trials seeking participants for Skin Cancer research studies. These trials are conducted in various cities, including Milwaukee, Madison, Green Bay and Marshfield.
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
NCT06608511
Recruiting
The goal of this observational study is to study blood samples and compare them to other biospecimens and clinical outcomes in participants who have melanoma or non-melanoma skin cancers. The main question it aims to answer is: * Are blood based signatures able to predict progression-free survival (PFS)? Participants undergoing regular treatment for their skin cancer will provide blood samples.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/08/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin, Site Unspecified, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
12/18/2024
Locations: Bellin Memorial Hospital, Green Bay, Wisconsin
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates